Loading clinical trials...
Loading clinical trials...
A Phase 1 Study of Sigvotatug Vedotin in Advanced Solid Tumors
Conditions
Interventions
sigvotatug vedotin
pembrolizumab
+2 more
Locations
158
United States
Alaska Oncology and Hematology
Anchorage, Alaska, United States
Highlands Oncology Group
Fayetteville, Arkansas, United States
Highlands Oncology Group
Rogers, Arkansas, United States
Highlands Oncology Group
Springdale, Arkansas, United States
Providence Medical Foundation
Anaheim, California, United States
Providence Medical Foundation
Fullerton, California, United States
Start Date
June 8, 2020
Primary Completion Date
June 16, 2027
Completion Date
March 22, 2029
Last Updated
April 20, 2026
NCT04895709
NCT05952934
NCT06385080
NCT06487403
NCT06242470
NCT05553782
Lead Sponsor
Seagen, a wholly owned subsidiary of Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions